Hydrophilic. Loadable. Durable. Scalable. Our patented nanogel platform is transforming medical device coatings — enabling multi-API delivery, superior passive protection, and a new approach to antimicrobial resistance.
CMD-COAT™ enhances device performance with exceptional coverage — all without disrupting existing manufacturing processes. Discover the innovations behind our solutions.
Advanced Coating Technology
Our entire coating system — from formulation to process and application — is water-based. This creates a highly stable, biocompatible foundation with no need for aggressive solvents.
Our advanced platform can be loaded with up to six APIs — both water-soluble or insoluble. The patented polymer system enables targeted, progressive release up to 30 days.
CMD-COAT™ forms an ultra-thin layer with exceptional bonding strength. It works on extremely narrow diameters and adapts to even the most sensitive or complex devices without affecting flexibility or function.
Even without APIs, CMD-COAT™ provides best-in-class device protection. The hydrophilic coating resists fouling from blood, proteins, and microbes — constantly protecting device surfaces.
A century after penicillin, we’re entering a new era of antibiotics. Our patented pyrimidine-based APIs reinvent how we target the bacterial cell wall — hitting multiple points to shut down even the toughest drug-resistant infections. This pleiotropic mechanism disrupts antimicrobial resistance, stopping infections at the source.
Antibiotic resistance is rising — turning manageable infections into serious threats. Our APIs work with antibiotics to enhance their effect, lower required doses, and have shown strong results in major clinical trials — with no known resistance.
Our patented API is built from a metabolite of an FDA-approved drug with full toxicology data. It delivers strong efficacy without added regulatory burden. When Fluometacyl® is paired with CMD-COAT™, it produces the first dual-action coating with both antimicrobial and antithrombotic properties.
Future Applications
Medical device coatings are just the beginning. Our APIs are built for two key paths:
CMD-COAT™ was engineered not just for performance, but for seamless integration into medical device manufacturing
— with no added time, complexity, or environmental burden.
Bloodstream infections from IV catheters can cost up to $46,000 per episode and carry a 15% mortality rate. Thrombosis affects up to 18% of patients, compounding risk and driving up costs. Existing coatings offer limited protection. CMD-COAT™ goes further.
Paired with our patented Fluometacyl® API, it delivers first-of-its-kind dual protection against both infection and thrombosis — all in a single, ultra-thin, hydrophilic layer.
CMD-COAT™ is designed to scale across insertable and implantable devices — and beyond.
$46k per episode
15% Mortality
Bloodstream Infection
$5k per episode
Increased Infection Risk
Thrombosis
IV catheters are just the beginning. Our nanogel platform, CMD-COAT™, is designed to enhance safety and performance across a wide range of medical devices — from high-risk insertables to long-term implants.
Potential applications span:
With programmable API delivery, exceptional passive protection, and potential for new API formats, it’s a new frontier for coating technology.
Behind this revolutionary platform is a team of leading clinicians, scientists, engineers, and business strategists working to change the future of medical device coatings and patient care.
